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Abstract
To identify suitable cases and reduce failure/complication rates for percutaneous ventricular septal defect (VSD) closure, we 
aimed to (1) study causes of device failure and (2) compare outcomes with different VSD types and devices in a high-volume 
single center with limited resources. Retrospective data of 412 elective percutaneous VSD closure of isolated congenital VSDs 
between 2003 and 2017 were analyzed. Out of 412, 363 were successfully implanted, in 30 device implantation failed, and in 
19 the procedure was abandoned. Outcome was assessed using echocardiography, electrocardiography, and catheterization 
data (before procedure, immediately after and during follow-up). Logistic regression analyses were performed to assess effects 
of age, VSD type, and device type and size on procedural outcome. Median [interquartile range] age and body surface area 
were 6.6 [4.1–10.9] years and 0.7 [0.5–1.0]  m2, respectively. Device failure was not associated with age (p = 0.08), type of 
VSD (p = 0.5), device type (p = 0.2), or device size (p = 0.1). Device failure occurred in 7.6% of patients. As device type is 
not related to failure rate and device failure and complication risk was not associated with age, it is justifiable to use finan-
cially beneficial ductal devices in VSD position and to consider closure of VSD with device in clinically indicated children.
Keywords Congenital ventricular septal defect · Percutaneous device closure · Amplatzer duct occluder · LifeTech ductal 
device
Introduction
Ventricular Septal Defect (VSD) is the most common con-
genital heart disease accounting for about 20% of all con-
genital heart defects in isolation [1]. Though VSDs can 
occur in any part of the interventricular septum, the major-
ity are perimembranous. The remainder are muscular (inlet, 
posterior, mid, outlet or anterior) in location, whereas less 
than10% are supracristal [2]. In very rare cases, VSDs can be 
acquired such as ventricular septal rupture following myo-
cardial infarction.
VSDs are commonly closed by open-heart surgery under 
cardiopulmonary bypass. Though surgical closure of a VSD 
is performed by experienced cardiac surgeons in dedicated 
cardiac hospitals, there remains a risk of bypass-related 
myocardial injury, complete AtrioVentricular Block (cAVB), 
blood transfusion [3], longer intensive care unit (ICU)/hos-
pital stay and higher chances of developing infections post-
operatively as compared to nonsurgical interventions.
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Transcatheter closure of VSD with a device is an alterna-
tive to surgery in selected anatomical variants of VSDs. The 
major advantage with the recent advances in percutaneous 
device closure is that it reduces the hospital stay significantly 
[3].
To analyze the outcome of VSD device closure, it’s 
imperative to know success rate, causes of device failure as 
well as complications that occurred during the procedure 
and in the post-procedural period. To that end we assessed 
the outcome of percutaneous device closure in various 
anatomical variants of VSDs while using different devices 
including alternative (nitinol wire) ductal devices such 
as Amplatzer Duct Occluder 1 (ADO1), Amplatzer Duct 
Occluder 2 (ADO2) (AGA medical corporation, Minnesota, 
USA) and LifeTech ductal device (LifeTech scientific, Shen-
zhen, China) in VSD position.
Methods
Retrospective data were collected of all patients who were 
taken for percutaneous device closure of congenital VSDs 
between January 2003 and December 2017 from hospi-
tal database. Pre-procedure electrocardiogram (ECG), 
echocardiography, chest radiograph and blood tests (Pro-
thrombin time, International Normalized Ratio, Activated 
Partial Thromboplastin Time and platelet count to rule out 
any bleeding disorders); during procedure hemodynamic 
catheterization data and fluoroscopy time; immediate post-
procedural and follow-up ECG, echocardiography and any 
complication/re-admission.
ECG and echocardiography was performed before and 
after device procedure (most by interventional cardiologists 
themselves) to assess the rhythm, exact location of the VSD, 
associated lesions, pulmonary arterial pressures, residual 
shunt, new onset of aortic and tricuspid regurgitations and 
pericardial effusion. Details of any complication during the 
course of hospitalization and subsequent treatments were 
noted.
Procedure: Access was via femoral artery and femoral or 
right internal jugular vein. Majority of VSDs were crossed 
from LV to RV using guide catheter and Terumo wire (Ashi-
taka factory of Terumo corporation, Fujinomiya city, Japan). 
The wire was advanced into the right/left pulmonary artery 
(RPA/LPA) and then snared out from the venous end using 
goose neck snare, forming an arteriovenous loop (AV loop). 
The delivery sheath/ guiding catheter was advanced over the 
wire covering the guide wire (Kissing technique) from the 
venous side. The tip of the delivery sheath was then posi-
tioned into the left ventricular (LV) apex (no special manipu-
lation used). Thereafter, the device was deployed through the 
delivery sheath under transthoracic echocardiography and 
fluoroscopic guidance. In some cases, the VSD was crossed 
from the LV side, using a right coronary artery (RCA) guid-
ing catheter which tip was placed in the RV. In these cases, 
the device was positioned from retrograde approach (no AV 
loop). Post-deployment LV and aortic angiograms were per-
formed to assess any residual shunt.
Cases were divided into three categories: 1. Success-
ful—where the device was successfully implanted into the 
heart; 2. Failed—where the device was selected and inserted 
into the heart and was found unsuitable while deploying the 
device; and 3. Abandoned—where the defect was found 
unsuitable for device closure after angiographic imaging, 
prior to opening the device from the company package.
Statistical analysis
Statistical analyses were performed using IBM SPSS Sta-
tistics for Windows (IBM Corp. Released 2017, Version 
25.0, Armonk, NY). Continuous variables were expressed 
as median with interquartile range. Categorical data were 
expressed as frequency with percentage.
Associations of outcome, device type, or VSD type with 
other predictors were assessed using (binomial or multino-
mial) logistic regression analyses. For potential continuous 
predictors, linearity was assessed by verifying that an addi-
tional quadratic term did not significantly improve modeling 
as quantified by a likelihood ratio (LR) test.
Regression models including VSD type were based on 
data for the four most common VSD types (1, 2, 4, and 5; 
Table 2) as inclusion of all types would lead to over-deter-
mination of logistic regression models. For the same reason, 
regression models including device type were based on data 
for device types 1, 2, 3, 4, and 9; Table 3. P values less than 
0.05 were considered statistically significant.
Results
Between January 2003 and December 2017, data on 433 per-
cutaneous VSD device closure were retrieved by retrospec-
tive collection from hospital medical records. After exclu-
sion of 21 cases (incomplete data, non-congenital acquired 
VSD), we analyzed 412 cases. Patient characteristics show-
ing all three categories (successful, failed and abandoned 
procedure) are listed in Table 1.
15 different types of devices were found in the database 
with 10 different anatomical variants of VSDs (Tables 2 and 
3). We studied the association of majorly used VSD devices 
(1, 2, 3, 4 and 9) and higher numbered VSDs (1, 2, 4, and 5) 
with device failure and association between Chinese versus 
American and muscular versus ductal devices in VSD posi-
tion using logistic regression analysis.
593Pediatric Cardiology (2020) 41:591–598 
1 3
Table 1  Patient characteristics 
stratified to VSD device 
outcome
Values denote median (interquartile range)
BSA body surface area, QP/QS pulmonary/systemic flow ratio, SPO2 peripheral oxygen saturation, VSD 
ventricular septal defect
Variable (unit) VSD device outcome
Successful (n = 363) Failed (n = 30) Abandoned (n = 19)
Age (years) 6.6 (4.1–10.9) 5.6 (3.7–8.5) 5.5 (3.2–9.1)
BSA  (m2) 0.7 (0.5–1.0) 0.6 (0.6–0.8) 0.7 (0.5–1.1)
SPO2 (%) 100 (98–100) 100 (98–100) 100 (98–100)
Heart rate (bpm) 100 (100–115) 100 (98–110) 110 (100–120)
VSD size (mm) 4 (3–4) 4 (4–5) 4 (4–5)
QP/QS 2.0 (1.6–2.3) 2.0 (1.7–2.3) 1.8 (1.7–2.0)
Fluoroscopy time (min) 14.1 (9.2–21.2) 18.9 (15.0–29.2) 17.3 (8.2–28.7)
Follow-up (days) 246 (71–764)
Table 2  Variants of VSD types
Values in first (total) column denote absolute frequency and percentage of each variant of VSD out of the 
total VSDs. The other columns denote the frequency and percentage of successful, failed and abandoned 
cases for each VSD variant
VSD type Total Successful Failed Abandoned
Perimembranous (1) 136 (33%) 120 (88%) 6 (4.4%) 10 (7.4%)
Posterior upper muscular (2) 156 (38%) 137 (88%) 14 (9.0%) 5 (3.2%)
Perimembranous upper muscular (3) 3 (0.7%) 2 (67%) 1 (33%) 0 (0.0%)
Upper muscular (4) 69 (16%) 62 (89%) 5 (7.2%) 2 (2.8%)
Mid muscular (5) 26 (6%) 23 (88%) 2 (7.6%) 1 (3.8%)
Lower muscular (6) 5 (1.2%) 4 (80%) 1 (20%) 0 (0.0%)
Anterior upper muscular (7) 7 (1.7%) 6 (85%) 1 (14%) 0 (0.0%)
Posterior mid muscular (8) 8 (2%) 8 (100%) 0 (0.0%) 0 (0.0%)
Anterior muscular (9) 1(0.25%) 1 (100%) 0 (0.0%) 0 (0.0%)
SubAortic (10) 1 (0.25%) 0 (0.0%) 0 (0.0%) 1 (100%)
Table 3  Variants of VSD 
devices and success/failure rate
Values in first (total) column denote absolute frequency and percentage of each variant of VSD device out 
of the total devices. The other columns denote the frequency and percentage of rate of successful and failed 
cases for each VSD device variant
Device type Total Successful Failed
Amplatzer ductal occluder-1 (1) 49 (12.5%) 43 (88%) 6 (12%)
Amplatzer ductal occluder-2 (2) 41 (10.4%) 35 (85%) 6 (15%)
LifeTech ventricular septal defect (3) 37 (9%) 32 (86%) 5 (13%)
LifeTech patent ductus arteriosus (4) 150 (38%) 142 (94%) 8 (5%)
LifeTech perimembranous (5) 2 (0.5%) 2 (100%) 0 (0.0%)
Amplatzer-muscular (6) 18 (4.5%) 18 (100%) 0 (0.0%)
Amender patent ductus arteriosus (7) 11 (2.8%) 11 (100%) 0 (0.0%)
Amender-ventricular septal defect (8) 7 (2%) 7 (100%) 0 (0.0%)
CardioFix ventricular septal defect (9) 38 (10%) 35 (92%) 3 (8%)
CardioFix-patent ductus arteriosus (10) 16 (4%) 16 (100%) 0 (0.0%)
CardioFix perimembranous (11) 4 (1%) 4 (100%) 0 (0.0%)
Blockade muscular (12) 13 (3.3%) 13 (100%) 0 (0.0%)
Blockade perimembranous (13) 4 (1%) 2 (50%) 2 (50%)
Cocoon (14) 2 (0.5%) 2 (100%) 0 (0.0%)
C-cure (15) 1 (0.5%) 1 (100%) 0 (0.0%)
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The distribution of major types of VSD and devices 
between successful and failed cases is shown in Fig. 1 and 
the distribution of 5 majorly used devices between success-
ful and failed cases over 15 years is shown in Fig. 2.
No significant association was found between probabil-
ity of device failure and subject age (p = 0.085), weight 
(p = 0.310), BSA (p = 0.382), or sex (p = 0.373; binomial 
logistic regression, LR tests).
Probability of device failure was also not significantly 
associated with VSD type (p = 0.536, binomial logistic 
regression, LR test) or with device type (p = 0.228, binomial 
logistic regression, LR test). There was also no difference in 
failure rate between muscular and ductal devices (p = 0.332, 
binomial logistic regression, LR test).
Devices were further divided into two categories based on 
the manufacturing country (United states and China). Prob-
ability of device failure was not significantly associated with 
manufacturing country (United States vs. China; p = 0.090, 
binomial logistic regression, LR test).
Out of 15 different type of VSD devices, LifeTech Patent 
Ductus Arteriosus (PDA) device was used most frequently 
(38%) with interestingly the lowest failure rate (5%); how-
ever, the difference was not statistically significant from 
other devices (p = 0.228) which could be due to lack of sta-
tistical power, as some device types were used in very small 
numbers.
There was no significant association between device size 
and probability of device failure (p = 0.168; binomial logistic 
Fig. 1  Distribution of cumulative frequencies of major VSD and 
device types between successful/failed. Device type and total number 
of its implantations are depicted next to the Y-axis on the left. The 
width of each horizontal block depicts the cumulative frequencies of 
the device used per different VSD type, with the absolute number of 
successful/failed cases depicted within the horizontal block. ADO1/2 
Amplatzer ductal occluder ½, CF CardioFix, LT LifeTech, MM mid 
muscular, PM perimembranous, PDA patent ductus arteriosus, PUM 
posterior upper muscular, UM upper muscular, VSD ventricular septal 
defect
Fig. 2  Distribution of five major VSD device types between success-
ful/failed cases over years. Device type and total number of the cor-
responding device are depicted next to the Y-axis on the right. The 
width of each horizontal block in different shades depicts the cumu-
lative frequency of the type of device used each year over 15 years, 
with the absolute number of successful/failed cases within the hori-
zontal block. ADO1/2 Amplatzer ductal occluder 1 or 2, CF Car-
dioFix, LT LifeTech, PDA patent ductus arteriosus, VSD ventricular 
septal defect
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regression, LR test), probability of aortic regurgitation (AR) 
(p = 0.087; binomial logistic regression, LR test) and tri-
cuspid regurgitation (TR) (p = 0.773; multinomial logistic 
regression, LR test).
Probability of success vs. failure significantly decreased 
with fluoroscopy time (p = 0.005 (LR test; χ2(1) = 7.82), 
β = − 0.048 (SE 0.017), binomial logistic regression with 
fluoroscopy time as a continuous predictor). Specifically, 
each additional minute of fluoroscopy time corresponds to 
a 4.7% reduction in the odds of a successful outcome. This 
indicates that failed device closures had longer radiation 
time which we attribute to technical difficulty.
The prevalence of new onset of AR (grade-1) was 15% 
immediate after device closure and reduced to 5% at median 
follow-up of 246 days (range 71–764). In the immediate 
post-device period, grade-1 TR was present in 48%, but this 
number reduced to 22% at follow-up. Mild left ventricle to 
right atrium (LV-RA) jet was present in 3% of the cases in 
immediate post-procedure period, and reduced to less than 
1% at follow-up. 3% of patients had tiny residual VSD at 
follow-up and 3% of patients had minor vascular compli-
cations in the immediate post-device period which did not 
require any intervention (Table 4).
Two patients had to undergo open-heart surgery due to 
major complications (tear in the aortic valve cusp and tri-
cuspid chordal rupture); one patient had device embolization 
5 days after the device procedure and one patient died due 
to intracranial bleeding (Table 4). The complications that 
required intervention are explained in detail in the discus-
sion section.
There was no major conduction or rhythm abnormality 
in the early post-procedure period. One patient, however, 
was re-admitted after 6 weeks with intermittent left bundle 
branch block (LBBB) with 1st degree atrioventricular (AV 
block) (0.28%). Because the patient’s 24-h Holter monitor-
ing did not warrant permanent pacemaker implantation, 
the patient was discharged and was advised follow-up. Out 
of 363 successful percutaneous VSD device closure cases, 
one case developed cAVB requiring permanent pacemaker 
implantation (0.28%) at follow-up of 1 year and 5 months.
Discussion
The present study reports the evaluation and comparison 
of different anatomical type of VSDs, various devices and 
the complications. Though various studies have shown 
good results previously [4–6], pre-procedural prediction of 
complications is difficult. We evaluated the cases from the 
pre-procedure period to follow-up for overall outcome and 
feasibility of using alternative devices (like PDA device) in 
VSD position.
According to our observation there was no significant 
association between device failure and patient’s age, weight, 
body surface area, type of VSD or the device used. Of note, 
device selection was decided depending on VSD morphol-
ogy rather than age at procedure with, preferentially, ductal 
devices for VSDs in membranous/upper muscular location, 
muscular VSD devices for muscular VSDs, and ADO2 with 
their softer profile for VSDs close to aortic valve. VSD 
Table 4  Outcome variables pre-device, immediate post-device and follow-up
Values denote frequency and percentage of each complication
cAVB complete atrioventricular block, EP electrophysiological, LBBB left bundle branch block, LPA left pulmonary artery, NCC non-coronary 
cusp
Outcome variable Time interval
Pre-device (n = 363) Immediate post-device within 
24 h (n = 363)
Follow-up (median 
246 (71–764) days) 
(n = 135)
Aortic regurgitation (grade-1) 2 (0.5%) 53 (14%) 7 (5%)
Tricuspid regurgitation (grade-1) 20 (5.5%) 173 (47%) 30 (22%)
LV-RA jet (Mild) 89 (24%) 10 (2.8%) 1 (0.7%)
Residual VSD (Tiny) – 34 (9.5%) 4 (3%)
Vascular complications – 12 (3%) –
Complications which needed intervention Time period post-device Cause Frequency (%)
Aortic valve repair (surgical) 2 months Torn NCC 1 (0.28%)
Tricuspid valve repair (surgical) 5 months Chordal rupture 1 (0.28%)
cAVB, permanent pacemaker implantation 1 and half year cAVB 1 (0.28%)
Embolization Next day Embolized in distal LPA 1 (0.28%)
Observation 1st degree AV Block with LBBB 6 weeks EP study didn’t warrant perma-
nent pacemaker implantation
1 (0.28%)
Death 5 days Intracranial bleeding 1 (0.28%)
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device closure procedure done at an experienced center 
can be successfully performed in carefully selected cases 
(preferably by interventional cardiologists themselves) with 
suitable morphology (VSD location and its relation to con-
duction tissue, and aortic/tricuspid valve).
Historically, children under age of 3 years undergoing 
device closure for VSDs located in the membranous region 
are considered to be at risk for developing cAVB [5, 7–9]. 
cAVB becomes important especially for VSDs located in 
membranous and inlet septum (due to their proximity to the 
AV node), whether the approach is surgical or with a device 
[6, 9].The incidence of heart block in surgically operated 
isolated VSDs requiring permanent pacemaker implantation 
is 28 (2.8%) out of 1000 cases in our high-volume center 
(unpublished data). In this series of 412 percutaneous VSD 
device closures, only one case developed cAVB. This was 
a 3-year-old child with a 4 mm posterior upper muscular 
VSD on echocardiography with mild LV-RA jet who had 
successful VSD closure with an 8/6 mm LifeTech PDA 
device. After device procedure there was no residual shunt, 
no LV-RA jet and no rhythm abnormality at the time of 
discharge. However, this patient presented to the hospital 
after 1 year 5 months post-procedure with cAVB (0.28%) 
for which epicardial VVIR pacemaker was implanted. This 
delayed complication of device closure, possibly due to 
fibrous tissue formation around the device [4], indicates that 
regular follow-up is needed because one cannot completely 
exclude the possibility of delayed cAVB despite an unevent-
ful immediate post-device period. Regarding type of device 
selection in relation to the age, was decided depending on 
the morphology of VSD rather than the age at procedure.
None of the five most commonly used devices had statis-
tically significant outcome predictors related to four majorly 
closed types of VSDs. This indicates that, when carefully 
chosen, neither the type of device nor various anatomical 
locations of VSDs influence the outcome. Interestingly the 
median VSD size in our population was 4 mm as VSDs in 
membranous/upper muscular location are usually restricted 
by tricuspid valve tissue or septal aneurysm on RV side, 
which makes them conical in shape. Hence, ductal devices 
(mainly ADO1 type) can be safely used in VSD position, 
particularly in perimembranous location, as it has only sin-
gle disc on LV side and no disc on right ventricular (RV) 
end. We believe this is the major reason for the low inci-
dence of cAVB and tricuspid valve issues. On the other hand 
muscular VSD devices are better suited for muscular VSDs. 
ADO2 are softer profile devices which can be considered 
for VSDs close to aortic valve. Larger VSDs are closed with 
large sized devices provided they are not close to aortic valve 
or conduction tissue.
It is important to look for new onset of valve regurgitation 
after the procedure. Because 33% of the cases from our data-
base had perimembranous VSD, which is in close proximity 
to aortic valve on LV side and tricuspid valve on RV side, 
careful assessment of AR and TR becomes important [4]. In 
our 363 successful cases, one patient had severe TR (4 mm 
muscular VSD device) at follow-up of 5 months; echocar-
diography showed torn chordae of tricuspid valve for which 
surgical tricuspid valve repair was done. Another patient 
developed severe AR at follow-up of 2 months requiring aor-
tic valve repair. At surgery it was noted that the device was 
away from the aortic valve, hence it was left in situ and only 
aortic valve repair was done. We believe that the AR was 
possible secondary to aortic valve damage while perform-
ing AV loop or pushing the delivery sheath across the valve 
(iatrogenic). Rest of the cases who had documented grade 
I AR (similar to trace AR-more physiological than patho-
logical AR) in post-procedure period could be partly due to 
catheter manipulation and inter-observer variation in assess-
ment of presence of AR. As being the main center where the 
procedure was done we have not had re-do for aortic valve 
except for one (above mentioned) case after device closure.
Of all the successful cases, 24% had LV-RA jet associated 
with VSD (mainly perimembranous/posterior upper muscu-
lar) which reduced to 2.8% immediately after the procedure 
and to 0.7% at follow-up. This shows that, due to endothe-
lialization and fibrosis, the device can eventually also cover 
the LV-RA jets associated with a VSD, especially in the 
region of pars atrioventricularis.
In the immediate post-procedure period, 34 (9%) patients 
had tiny residual leak out of which 1 was hemodynamically 
significant (0.28%) with large L-R shunt. Interestingly we 
observed that at median follow-up of 246 (71–764) days 
small residual leaks reduced to 4 (3%) cases. This could be 
due to the endothelialization of the device that can close 
the tiny residual leaks usually seen immediately after the 
procedure.
Large device size and longer fluoroscopy time are of 
concern for developing post-procedure arrhythmias [6]. In 
our study fluoroscopy time was longer for failed device and 
abandoned procedure categories; this could be due to techni-
cal difficulty in crossing the VSD.
There was no association of device size and device failure 
or rhythm abnormality. One patient developed transient atri-
oventricular (AV) block with atrial fibrillation during clo-
sure with ADO1 device of posterior upper muscular VSD. 
Because the patient reverted to sinus rhythm on table, the 
device was successfully deployed. Though this patient was 
re-admitted with 1st degree AV block with LBBB, no further 
intervention was done as 24 h holter monitoring was normal. 
Though LBBB is a rare complication seen after device clo-
sure [4, 7, 10], it’s important to advice for early follow-up 
and review ECG (less than 4 weeks) for patients who had 
rhythm abnormality during the procedure.
Technical difficulty in crossing the defect was found 
in VSDs located in lower muscular septum and in VSDs 
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covered with large septal aneurysms with multiple sieve-
like openings.
Hemolysis is another complication that is known to hap-
pen soon after device closure in 1% of cases [4, 7]. Hemoly-
sis occurs more commonly in cases with significant residual 
shunts after device closure, due to mechanical injury to red 
blood cells. Hemolysis can be minimal and resolve on its 
own. However, when severe it may warrant urgent surgi-
cal removal of the device [11]. In our observation from the 
database there were no cases with hemolysis.
In our study the only patient with significant residual 
VSD post-procedure was unresponsive within 12 h after pro-
cedure due to intracranial bleeding and subsequently died. 
Patient’s pre-procedure coagulation status was normal. Our 
postulation is bleeding might have been secondary to (a) 
intravenous heparin as per protocol (100 UNIT/Kg body 
weight), (b) intracranial pathology such as aneurysm in the 
circle of Willis etc. and (c) acute hemodynamic changes that 
occur during induction of anesthesia (e.g., ketamine used in 
this patient could have increased intracranial pressure), or 
(d) more likely to be a combination of above factors.
Limitations
The main limitation is that the study is retrospective (com-
plete availability of the data we can access from records is 
not in our control), we lack the long-term follow-up, which 
is very important to assess possible late complications and 
it is a single-centered study.
Conclusion
In our observation device failure was neither associated with 
the age at procedure nor with the type of VSD or device 
used. Considering the low incidence of major complications, 
it does not seem necessary to postpone percutaneous VSD 
closure when indicated, even in smaller children. As ductal 
devices were used in VSD closure in majority of cases, it is 
justifiable to use financially beneficial ductal devices in VSD 
position. However, long-term follow-up study to rule out late 
complications is indicated.
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